Real World Evidence Solutions Market worth $12.44 billion by 2031 - Exclusive Report by MarketsandMarkets™

MarketsandMarkets forecasts the global real-world evidence solutions market will double to $12.44 billion by 2031 from $6.22 billion in 2026, a 14.9% CAGR. Growth is being driven by value-based care, pharmaceutical and medtech R&D, expanding EHR and claims datasets, and AI-enabled, privacy-preserving evidence-generation tools. North America held a 58.3% market share in 2025, while datasets are projected to be the fastest-growing component at a 15.5% CAGR; recent investments and acquisitions underscore consolidation around integrated RWE data and analytics platforms.

Analysis

This is a modestly positive read-through for scaled RWE incumbents, but not an earnings-moving event by itself. IQV and ICLR are best positioned because regulatory-grade evidence monetizes through study design, therapeutic expertise and sponsor relationships—not merely data storage; the likely economic effect is a mix shift toward higher-value, recurring evidence programs that can support utilization and margins over 6-18 months. FTRE has more operating leverage if biopharma outsourcing budgets recover, but its smaller scale and integration history make execution risk higher.

The non-obvious competitive pressure falls on point-solution data vendors: AI lowers the cost of querying, cohort creation and draft analytics, but it does not solve data provenance, patient linkage, auditability or regulatory acceptance. That favors Datavant/Aetion privately and IQV/Optum/Oracle commercially, while PLTR and ORCL can capture infrastructure spend without necessarily owning the clinical-services economics. ONMD is a high-beta watch rather than a validated beneficiary: subscription conversion and paid-data access are the critical missing KPIs.

Near term, consensus may over-extrapolate a broad "healthcare AI" revenue opportunity from an industry forecast. Procurement cycles at large pharma and payers remain long, and incremental RWE spend may displace legacy CRO or commercial-analytics budgets before expanding total spend. The thesis is falsified if IQV/ICLR report flat RWE-related bookings, declining book-to-bill, or if privacy/regulatory constraints delay cross-dataset linkage; conversely, disclosed multiyear platform wins or improved services utilization would validate a 1-3 month rerating catalyst.

Key Decisions for Investors

• Accumulate IQV on market weakness for a 6-12 month hold; it is the cleanest public RWE exposure with diversification across data, technology and services. Target a 10-15% upside on evidence of improving bookings/margin mix; exit if organic growth or book-to-bill weakens for two consecutive quarters.
• Pair long IQV / short FTRE over 3-6 months: both benefit from outsourcing normalization, but IQV should command superior multiple resilience through proprietary data and platform breadth. Size for a 10-15% relative-return objective; cover if FTRE reports materially stronger new-business awards or sustained utilization inflection.
• Maintain PLTR and ORCL as second-order beneficiaries rather than primary RWE trades. Add only after disclosed healthcare-data subscription wins or material Foundry/cloud consumption evidence; absent segment disclosure, the addressable-market forecast is insufficient to underwrite incremental revenue.
• Place an alert on ONMD for verified annual recurring revenue, net-retention and multiyear contract disclosures. Consider a small speculative long only after evidence that customer evaluations convert to paid subscriptions; lack of such disclosure by the next two reporting periods invalidates the recurring-revenue narrative.